USPTO serial 98403668
VITA GLOBAL SCIENCES
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- FRENCH, CURTIS W
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with VITA GLOBAL SCIENCES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ashish D. Patel
Ashish D. Patel Thompson Hine LLP3560 Lenox Road NE, Suite 1600Atlanta, GA 30326-4266United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Business consultation in the life sciences and pharmaceutical industries, namely in the fields of clinical operations management, clinical data management, clinical project management, clinical trial management, clinical IT, biostatistics, statistical programming, medical writing, and regulatory submission management; Business consulting and management for the life sciences and pharmaceutical industries to assist companies with regulatory submissions and drug approval, namely, providing clinical operations management, clinical data management, clinical project management, clinical trial management, clinical IT, biostatistics, statistical programming, medical writing, and regulatory submission management; Analyzing and compiling business data for others in the life sciences and pharmaceutical fields; Employment staffing consultation services in the fields of clinical operations management, clinical data management, clinical project management, clinical trial management, clinical IT, biostatistics, statistical programming, medical writing, and regulatory submission management, in each case, in the life sciences and pharmaceutical industries; Employment staffing and recruitment services in the fields of clinical operations management, clinical data management, clinical project management, clinical trial management, clinical IT, biostatistics, statistical programming, medical writing, and regulatory submission management, in each case, in the life sciences and pharmaceutical industries; business project management services for others in the life sciences and pharmaceutical industries, namely clinical operations management, clinical data management, clinical project management, clinical trial management, clinical IT, biostatistics, statistical programming, medical writing, and regulatory submission management; Business services, namely, formulation of best practices for researchers and medical professionals, formulation of best practices for conducting clinical trials and manufacturing pharmaceuticals, and serving as a functional service provider in the fields of clinical operations management, clinical data management, clinical project management, clinical trial management, clinical IT, biostatistics, statistical programming, medical writing, and regulatory submission management; Business consulting and management, namely regulatory submission and clinical trial management, namely, analyzing, verifying, and compiling medical data; Analyzing and compiling business data for others in the field of regulatory submission preparation and compliance | ACTIVE | — |
| 045 | Regulatory project management services for others in the fields of life sciences and pharmaceuticals; Regulatory compliance consulting in the fields of life sciences and pharmaceuticals; Regulatory consulting services for others in the fields of life sciences and pharmaceuticals, namely, reviewing standards and practices of others to assure compliance with government and industry laws and regulations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 1, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 30, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 30, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 30, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 19, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 18, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 18, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 18, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 8, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 13, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 13, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 7, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 10, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 9, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 9, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 4, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Dec 4, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Sep 9, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 5, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 6, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 6, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 6, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 13, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 13, 2024 | NWAP | NEW APPLICATION ENTERED | — |